

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of:
Rosen et al.

Docket No.: PF596P1N

Patent No.: 7,601,351

Issued: October 13, 2009

For: Antibodies Against Protective Antigen

**REQUEST FOR CERTIFICATE OF CORRECTION
PURSUANT TO 37 CFR 1.322**

Attention: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Upon reviewing the above-identified patent, Patentee noted typographical errors which should be corrected.

At Item (56) References Cited – Other Publications:

Please delete ““Anthrax,” Internet publication by National Organization of Rare Disorders (NORD), 2001.” and insert therefor --“Anthrax,” Internet publication by National Organization of Rare Disorders (NORD), 2001.--

Please delete “Brossier et al., “Anthrax Spores Make an Essential Contribution to Vaccine Efficacy,” *Infect. Immun.*, 70:661-664 (Feb. 2002).” and insert therefor --Brossier et al., “Anthrax Spores Make an Essential Contribution to Vaccine Efficacy,” *Infect. Immun.*, 70:661-664 (Feb. 2002).--

Please delete “Ezzell et al., “Immunoelectrophoretic Analysis, Toxicity, and Kinetics of In vitro Production of the Protective Antigen and Lethal Factor Components of *Bacillus anthracis* Toxin,” *Infect. Immun.*, 45:761-767 (Sep. 1984).” and insert therefor --Ezzell et al., “Immunoelectrophoretic Analysis, Toxicity, and Kinetics of In Vitro Production of the Protective Antigen and Lethal Factor Components of *Bacillus anthracis* Toxin,” *Infect. Immun.*, 45:761-767 (Sep. 1984).--

Please delete “Friedlander, A.M., “Chapter 22: Anthrax,” in *Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare*. Specialty eds: Sidell, F.R., et

al., (The Office of the Surgeon General at TMM Publications, Borden Institute, Walter Reed Army Medical Center, Washington, DC) pp. 467-478 (1997).” and insert therefor --Friedlander, A.M., “Chapter 22: Anthrax,” in *Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Specialty eds: Sidell, F.R., et al.,* (The Office of the Surgeon General at TMM Publications, Borden Institute, Walter Reed Army Medical Center, Washington, DC) pp. 467-478 (1997).--

Please delete “Friedlander, A.M., “Anthrax: Clinical Features, Pathogenesis, and Potential Biological Warfare Threat,” *Curr. Clinic. Topic Infect. Dis.*, 20:335-349 (2000).” and insert therefor --Friedlander, A.M., “Anthrax: Clinical Features, Pathogenesis, and Potential Biological Warfare Threat,” *Curr. Clinic. Topics Infect. Dis.*, 20:335-349 (2000).--

Please delete “Inglesby et al., “Anthrax as a Biological Weapon, 2002 Updated Recommendations for Management,” *JAMA*, 287:2236-2252 (May 1, 2002); (reprinted with corrections as set forth in *JAMA* 288:1849 (Oct. 16, 2002).” and insert therefor --Inglesby et al., “Anthrax as a Biological Weapon, 2002 Updated Recommendations for Management,” *JAMA*, 287:2236-2252 (May 1, 2002); (reprinted with corrections as set forth in *JAMA* 288:1849 (Oct. 16, 2002)).--

Please delete “Ramirez et al., “Production, recovery and Immunogenicity of the protective antigen from a recombinant strain of *Bacillus anthracis*,” *J. Indust. Microbiol. Biotech.*, 28:232-238 (2002).” and insert therefor --Ramirez et al., “Production, recovery and immunogenicity of the protective antigen from a recombinant strain of *Bacillus anthracis*,” *J. Indust. Microbiol. Biotech.*, 28:232-238 (2002).--

Please delete “Read et al., “Comparative Genome Sequencing for Discovery of Novel Polymorphisms in *Bacillus anthracis*,” *Science*, 296:2028-2033 (Jun. 14, 2002).” and insert therefor --Read et al., “Comparative Genome Sequencing for Discovery of Novel Polymorphisms in *Bacillus anthracis*,” *Science*, 296:2028-2033 (Jun. 14, 2002).--

Please delete “Sabourin et al., “Short Duration Ciprofloxacin® Therapy Provides High Protection to Non-Human Primates Challenged With Aerosolized *B. Anthracis* Spores,” presented at Bacillus ACT Conference-2005, Santa Fe, NM, September 25-29, 2006 (abstract only).” and insert therefor --Sabourin et al., “Short Duration Ciprofloxacin® Therapy Provides High Protection to Non-Human Primates Challenged With Aerosolized *B. Anthracis* Spores,” presented at Bacillus ACT Conference-2005, Santa Fe, NM, September 25-29, 2006 (abstract only).--

Please delete “Singh et al., “The Carboxyl-terminal End of Protective Antigen Is Required for Receptor Binding and Anthrax Toxin Activity,” *J. Biol. Chem.*, 266:15493-15497 (Aug. 15, 1991).” and insert therefor --Singh et al., “The Carboxyl-terminal End of Protective Antigen Is Required for Receptor Binding and Anthrax Toxin Activity,” *J. Biol. Chem.*, 266:15493-15497 (Aug. 15, 1991).--

In the Specification:

At column 114, line 3, please delete “dasone” and insert therefor --dapsons--.

At column 142, in the last line of Table 4, please delete “QQSLTAWV” and insert therefor --QQSLTAWT--.

Support for the correction of the publications can be found in the Information Disclosure Statement filed by applicants on July 11, 2006.

Support for the correction to the specification can be found in the Second Preliminary Amendment filed by applicants on January 16, 2007 and the Amendment and Response Under 37 C.F.R. § 1.116 filed by applicants on October 28, 2008.

The errors were not in the application as filed or amended by Applicants; accordingly no fee is required.

Transmitted herewith is a proposed Certificate of Correction effecting such amendment. Patentee respectfully solicits the granting of the requested Certificate of Correction.

Dated: December 10, 2009

Respectfully submitted,

/Mark J. Hyman/

Mark J. Hyman

Registration No.: 46,789

HUMAN GENOME SCIENCES, INC.

Intellectual Property Dept.

14200 Shady Grove Road

Rockville, Maryland 20850

(240) 314-1224

MJH/JE/ba

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 3

PATENT NO. : 7,601,351
APPLICATION NO. : 10/602,727
ISSUE DATE : October 13, 2009
INVENTOR(S) : Rosen et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At Item (56) References Cited – Other Publications:

Delete ““Anthrax,” Internet publication by National Organization of Rare Disorders (NORD), 2001.” and insert --“Anthrax,” Internet publication by National Organization of Rare Disorders (NORD), 2001.--

Delete “Brossier et al., “Anthrax Spores Make an Essential Contribution to Vaccine Efficacy,” *Infect. Immun.*, 70:661-664 (Feb. 2002).” and insert --Brossier et al., “Anthrax Spores Make an Essential Contribution to Vaccine Efficacy,” *Infect. Immun.*, 70:661-664 (Feb. 2002).--

Delete “Ezzell et al., “Immunoelectrophoretic Analysis, Toxicity, and Kinetics of In vitro Production of the Protective Antigen and Lethal Factor Components of *Bacillus anthracis* Toxin,” *Infect. Immun.*, 45:761-767 (Sep. 1984).” and insert --Ezzell et al., “Immunoelectrophoretic Analysis, Toxicity, and Kinetics of In Vitro Production of the Protective Antigen and Lethal Factor Components of *Bacillus anthracis* Toxin,” *Infect. Immun.*, 45:761-767 (Sep. 1984).--

Delete “Friedlander, A.M., “Chapter 22: Anthrax,” in *Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare*. Specialty eds: Sidell, F.R., et al., (The Office of the Surgeon General at TMM Publications, Borden Institute, Walter Reed Army Medical Center, Washington, DC) pp. 467-478 (1997).” and insert --Friedlander, A.M., “Chapter 22: Anthrax,” in *Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare*. Specialty eds: Sidell, F.R., et al., (The Office of the Surgeon General at TMM Publications, Borden Institute, Walter Reed Army Medical Center, Washington, DC) pp. 467-478 (1997).--

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Mark J. Hyman
HUMAN GENOME SCIENCES, INC.
Intellectual Property Dept.
14200 Shady Grove Road
Rockville, Maryland 20850

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 3

PATENT NO. : 7,601,351
APPLICATION NO. : 10/602,727
ISSUE DATE : October 13, 2009
INVENTOR(S) : Rosen et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Cont'd

Delete "Friedlander, A.M., "Anthrax: Clinical Features, Pathogenesis, and Potential Biological Warfare Threat," *Curr. Clinic. Topic Infect. Dis.*, 20:335-349 (2000)." and insert --Friedlander, A.M., "Anthrax: Clinical Features, Pathogenesis, and Potential Biological Warfare Threat," *Curr. Clinic. Topics Infect. Dis.*, 20:335-349 (2000).--

Delete "Inglesby et al., "Anthrax as a Biological Weapon, 2002 Updated Recommendations for Management," *JAMA*, 287:2236-2252 (May 1, 2002); (reprinted with corrections as set forth in *JAMA* 288:1849 (Oct. 16, 2002))." and insert --Inglesby et al., "Anthrax as a Biological Weapon, 2002 Updated Recommendations for Management," *JAMA*, 287:2236-2252 (May 1, 2002); (reprinted with corrections as set forth in *JAMA* 288:1849 (Oct. 16, 2002)).--

Delete "Ramirez et al., "Production, recovery and Immunogenicity of the protective antigen from a recombinant strain of *Bacillus anthracis*," *J. Indust. Microbiol. Biotech.*, 28:232-238 (2002)." and insert --Ramirez et al., "Production, recovery and immunogenicity of the protective antigen from a recombinant strain of *Bacillus anthracis*," *J. Indust. Microbiol. Biotech.*, 28:232-238 (2002).--

Delete "Read et al., "Comparative Genome Sequencing for Discovery of Novel Polymorphisms in *Bacillus anthracis*," *Science*, 296:2028-2033 (Jun. 14, 2002)." and insert --Read et al., "Comparative Genome Sequencing for Discovery of Novel Polymorphisms in *Bacillus anthracis*," *Science*, 296:2028-2033 (Jun. 14, 2002).--

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Mark J. Hyman
HUMAN GENOME SCIENCES, INC.
Intellectual Property Dept.
14200 Shady Grove Road
Rockville, Maryland 20850

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 3 of 3

PATENT NO. : 7,601,351
APPLICATION NO. : 10/602,727
ISSUE DATE : October 13, 2009
INVENTOR(S) : Rosen et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Cont'd

Delete "Sabourin et al., "Short Duration Ciprofloxacin® Therapy Provides High Protection to Non-Human Primates Challenged With Aerosolized *B. Anthracis* Spores," presented at Bacillus ACT Conference-2005, Santa Fe, NM, September 25-29, 2006 (abstract only)." and insert --Sabourin et al., "Short Duration Ciprofloxacin® Therapy Provides High Protection to Non-Human Primates Challenged With Aerosolized *B. Anthracis* Spores," presented at Bacillus ACT Conference-2005, Santa Fe, NM, September 25-29, 2006 (abstract only).--

Delete "Singh et al., "The Carboxyl-terminal End of Protective Antigen Is Required for Receptor Binding and Anthrax Toxin Activity," *J. Biol. Chem.*, 266:15493-15497 (Aug. 15, 1991)." and insert --Singh et al., "The Carboxyl-terminal End of Protective Antigen Is Required for Receptor Binding and Anthrax Toxin Activity," *J. Biol. Chem.*, 266:15493-15497 (Aug. 15, 1991).--

In the Specification:

At column 114, line 3, delete "dasone" and insert --dapsons--.

At column 142, in the last line of Table 4, delete "QQSLTAWV" and insert --QQSLTAWT--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Mark J. Hyman
HUMAN GENOME SCIENCES, INC.
Intellectual Property Dept.
14200 Shady Grove Road
Rockville, Maryland 20850